Aims
Heart rate was proposed as an emergent cardiovascular (CV) risk factor. Previous studies have shown associations between increased heart rate and CV risk in various populations. We aimed to evaluate the prognostic relevance of heart rate in a large contemporaneous medically optimized cohort of patients with stable chronic CV disease.
Methods and results
In a post hoc analysis of the ONTARGET/TRANSCEND trials, we evaluated associations between baseline and average heart rate in trial with CV risk in 31, 531 patients followed for a median of 5 years. The primary outcome, major vascular events (MVE), was a composite of CV death, myocardial infarction (MI), stroke, and congestive heart failure (CHF). Pre-specified secondary outcomes included all-cause death and the individual components of the primary outcome. Associations between heart rate and outcomes were computed with heart rate as a continuous variable, baseline heart rate >70 vs ≤70 bpm, and across heart rate quintiles, adjusting for other markers of risk, beta-blocker and non-dihydropyridine calcium channel blocker use. For each 10 bpm increase in baseline and average heart rate, we observed a significant increase in risk of MVE, CV death, CHF and all-cause death. There was a continuous relationship between MVE and baseline and, more importantly, average in-trial heart rate, with no observed threshold. MVE, CV death, stroke, CHF, and all-cause death increased across heart rate quintiles. There was no association between MI and HR. Results were consistent in clinically relevant subgroups. There were modest but significant improvements in C-statistic and in statistical measures of model calibration for models that included heart rate for MVE, CV death, CHF and all-cause death.
Conclusions
This large study examined and quantitated associations between heart rate and CV events in a contemporary medically optimized population with stable CV disease. Resting and, in particular, in-trial average heart rate are independently associated with significant increases in CV events and all-cause death.
Similar content being viewed by others
References
Palatini P, Julius S (2004) Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hyperten 26:637–644
Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112:736–749
Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 113:1489–1494
Gillum RF, Makuc DM, Feldman JJ (1991) Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J 121:172–177
Gillman MW, Kannel WB, Belanger A, D’Agostino RB (1993) Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 125:1148–1154
Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, de Leeuw PW, Jaaskivi M, Leonetti G, Nachev C, O’Brien ET, Parati G, Rodicio JL, Roman E, Sarti C, Tuomilehto J (2002) Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 162:2313–2321
Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ (2008) Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trandolapril Study (INVEST). Eur Heart J 29:1327–1334
Shaper AG, Wannamethee G, Macfarlane PW, Walker M (1993) Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men. Br Heart J 70:49–55
Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, For the GUSTO-I Investigators (1995) Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. Circulation 91:1659–1668
Zuanetti G, Mantini L, Hernández-Bernal F, Barlera S, di Gregorio D, Latini R, Maggioni AP (1999) Relevance of heart rate as a prognostic factor in myocardial infarction: the GISSI experience. Eur Heart J 1(Suppl J):H52–H57
Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967–974
Ho JE, Bittner V, Demicco DA, Breazna A, Deedwania PC, Waters DD (2010) Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (data from the Treating to New Targets [TNT] Trial). Am J Cardiol 105:905–911
Bangalore S, Messerli FH, Ou FS, Tamis-Holland J, Palazzo A, Roe MT, Hong MK (2010) Peterson ED; CRUSADE Investigators. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J 5:552–560
Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821
Böhm M, Swedberg K, Komajda M, Borer J, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, On behalf of the SHIFT investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894
Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:2377–2387
Beere PA, Glagov S, Zarins CK (1984) Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226:180–182
Perski A, Hamsten A, Lindvall K, Theorell T (1988) Heart rate correlates with severity of coronary atherosclerosis in young post infarction patients. Am Heart J 116:1369–1373
ONTARGET Investigators, Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:154–159
Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183
Böhm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PM, Yusuf S, Diener HC (2012) Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J 33:2804–2812
Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983
Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, Tavazzi L, Laufs U, Böhm M (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19
Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477–1482
Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159:585–592
Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolazzi A, D’Este D, Pegoraro F, Milani L, Mos L, HARVEST Study Group (2006) Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 24:1873–1880
Vergnaud AC, Protogerou AD, Li Y, Czernichow S, Vesin C, Blacher J, Safar ME (2008) Pulse pressure amplification, adiposity and metabolic syndrome in subjects under chronic antihypertensive therapy: the role of heart rate. Atherosclerosis 199:222–229
Lohse MJ, Engelhardt S, Danner S, Böhm M (1996) Mechanisms of beta-adrenergic receptor desensitization: from molecular biology to heart failure. Basic Res Cardiol 91(suppl 2):29–34
Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885
Snappin S, Iglewicz B (2005) Illustrating the impact of a time-varying covariate with an extended Kaplan–Meier indicator. Am Stat 59:301–307
Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Yusuf S, Heart Outcomes Prevention Evaluation (HOPE) Investigators (2001) Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104:1615–1621
Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S, ONTARGET investigators (2009) Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 27(7):1360–1369
Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O’Donnell CJ, Smith SC Jr, Wilson PW, American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119:2408–2416
Cook N (2008) Statistical evaluation of prognostic versus diagnostic models. Clin Chem 54:17–23
Conflict of interest
All authors obtained scientific support by Boehringer Ingelheim. The ONTARGET/TRANSCEND trial was sponsored by Boehringer Ingelheim.
Ethical standard statement
The study was performed according to the Declaration of Helsinki. The approval was given by the ethical committees of the study centers participating in the ONTARGET/TRANSCEND trial.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the ONTARGET/TRANSCEND Investigators. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique Identifier NCT 00153101.
Rights and permissions
About this article
Cite this article
Lonn, E.M., Rambihar, S., Gao, P. et al. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clin Res Cardiol 103, 149–159 (2014). https://doi.org/10.1007/s00392-013-0644-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-013-0644-4